TIA
MCID: TRN015
MIFTS: 56

Transient Cerebral Ischemia (TIA) malady

Categories: Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Transient Cerebral Ischemia

Aliases & Descriptions for Transient Cerebral Ischemia:

Name: Transient Cerebral Ischemia 12 52 14 69
Transient Ischemic Attack 12 51 52 41 14 69
Transient Cerebral Ischemia [ambiguous] 12
Tia - Transient Ischaemic Attack 12
Transient Cerebral Ischaemia Nos 12
Transient Cerebral Ischaemia 12
Transient Ischemic Attacks 12
Ischemic Attack, Transient 42
Tia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:224
ICD10 33 G45.9
ICD9CM 35 435.8
MeSH 42 D002546
NCIt 47 C50781

Summaries for Transient Cerebral Ischemia

MedlinePlus : 41 a transient ischemic attack (tia) is a stroke lasts only a few minutes. it happens when the blood supply to part of the brain is briefly blocked. symptoms of a tia are like other stroke symptoms, but do not last as long. they happen suddenly, and include numbness or weakness, especially on one side of the body confusion or trouble speaking or understanding speech trouble seeing in one or both eyes difficulty walking dizziness loss of balance or coordination most symptoms of a tia disappear within an hour, although they may last for up to 24 hours. because you cannot tell if these symptoms are from a tia or a stroke, you should go to the hospital right away. tias are often a warning sign for future strokes. taking medicine, such as blood thinners, may reduce your risk of a stroke. your doctor might also recommend surgery. you can also help lower your risk by having a healthy lifestyle. this includes not smoking, not drinking too much, eating a healthy diet, and exercising. it is also important to control other health problems, such as high blood pressure and cholesterol. nih: national institute of neurological disorders and stroke

MalaCards based summary : Transient Cerebral Ischemia, also known as transient ischemic attack, is related to mini stroke and moyamoya disease, and has symptoms including angina pectoris, back pain and chest pain. An important gene associated with Transient Cerebral Ischemia is ODC1 (Ornithine Decarboxylase 1), and among its related pathways/superpathways are Allograft rejection and MAPK signaling pathway. The drugs Aspirin and Valsartan have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and heart, and related phenotypes are cellular and homeostasis/metabolism

NINDS : 51 A transient ischemic attack (TIA) is a transient stroke that lasts only a few minutes. It occurs when the blood supply to part of the brain is briefly interrupted. TIA symptoms, which usually occur suddenly, are similar to those of stroke but do not last as long. Most symptoms of a TIA disappear within an hour, although they may persist for up to 24 hours. Symptoms can include: numbness or weakness in the face, arm, or leg, especially on one side of the body; confusion or difficulty in talking or understanding speech; trouble seeing in one or both eyes; and difficulty with walking, dizziness, or loss of balance and coordination.

Wikipedia : 71 A transient ischemic attack (TIA) is a transient episode of neurologic dysfunction caused by ischemia... more...

Related Diseases for Transient Cerebral Ischemia

Diseases related to Transient Cerebral Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 41)
id Related Disease Score Top Affiliating Genes
1 mini stroke 11.6
2 moyamoya disease 11.3
3 ischemia 11.0
4 cerebritis 11.0
5 hirschsprung disease 1 10.8
6 stroke, ischemic 10.8
7 neuronitis 10.6
8 muscular dystrophy-dystroglycanopathy , type a, 12 10.1 CCL2 IL1B
9 pigmentation disease 10.0 CCL2 IL1B ODC1
10 endotheliitis 10.0
11 interval angle-closure glaucoma 10.0 CCL2 IL1B
12 pontocerebellar hypoplasia type 2c 10.0 CASP3 HSPA4 HSPA5
13 apocrine adenosis of breast 9.9 CASP3 HSPA1A MAP2
14 bladder hepatoid adenocarcinoma 9.9 CASP3 HSPA1A MAP2
15 hyperglycemia 9.9
16 substance-induced psychosis 9.9 CASP3 CCL2 IL1B MAPT
17 ovarian mucinous adenocarcinoma 9.8 CASP3 GRIN2A IL1B MAP2
18 brain injury 9.8
19 hypoxia 9.8
20 vaginal spindle cell epithelioma 9.8 IL1B MAP2 MAPT
21 immunodeficiency due to defect in mapbp-interacting protein 9.7 CASP3 CCL2 HSPA4 IL1B ODC1
22 mucinous ovarian cystadenoma 9.7 CASP3 HSPA1A HSPA4 MAP2
23 prosopagnosia 9.7
24 adenoma 9.6
25 thyroiditis 9.6
26 middle cerebral artery infarction 9.6
27 cardiac arrest 9.6
28 amaurosis fugax 9.6
29 chlamydia 9.6
30 aneurysm 9.6
31 transient global amnesia 9.6
32 headache 9.6
33 patent foramen ovale 9.6
34 hypothyroidism 9.6
35 vascular disease 9.6
36 dermoid cyst 9.6
37 atrial septal aneurysm 9.6
38 cockayne syndrome 9.6
39 pneumonia 9.6
40 long qt syndrome 5 9.4 CASP3 HSPA4 HSPA5 MAP2 MAPT SLC1A1
41 cervix disease 7.9 CASP3 CCL2 DRD1 GCKR GRIN2A HSPA1A

Comorbidity relations with Transient Cerebral Ischemia via Phenotypic Disease Network (PDN): (show top 50) (show all 88)


Active Peptic Ulcer Disease Acute Cystitis
Acute Myocardial Infarction Alzheimer Disease
Anxiety Disorder Aortic Atherosclerosis
Atrioventricular Block Basilar Artery Insufficiency
Benign Essential Hypertension Benign Paroxysmal Positional Nystagmus
Bronchitis Bronchopneumonia
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Chronic Kidney Failure
Chronic Maxillary Sinusitis Chronic Myocardial Ischemia
Communicating Hydrocephalus Conjunctivitis
Conversion Disorder Cystitis
Decubitus Ulcer Deficiency Anemia
Diabetic Polyneuropathy Dysthymic Disorder
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophagitis Facial Paralysis
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Heart Conduction Disease Heart Disease
Hyperlipoproteinemia Type Iv Hypertension, Essential
Hypertensive Encephalopathy Hypoglycemia
Hypoglycemic Coma Hypothyroidism
Inner Ear Disease Intermediate Coronary Syndrome
Intracranial Embolism Intracranial Thrombosis
Iron Deficiency Anemia Ischemic Heart Disease
Kidney Disease Labyrinthitis

Graphical network of the top 20 diseases related to Transient Cerebral Ischemia:



Diseases related to Transient Cerebral Ischemia

Symptoms & Phenotypes for Transient Cerebral Ischemia

UMLS symptoms related to Transient Cerebral Ischemia:


angina pectoris, back pain, chest pain, edema, headache, pain, sciatica, seizures, syncope, tremor, amaurosis fugax, transient ischemic attacks, differing symptoms, transient ischemic attacks, stereotypic symptoms, chronic pain, vertigo/dizziness, sleeplessness

MGI Mouse Phenotypes related to Transient Cerebral Ischemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.85 LCN2 MAPT NOTCH3 ODC1 PTK2B SLC1A1
2 homeostasis/metabolism MP:0005376 9.7 CASP3 DRD1 GCKR HSPA5 IL1B KMO
3 nervous system MP:0003631 9.32 CASP3 DRD1 GRIN2A HSPA4 HSPA5 IL1B

Drugs & Therapeutics for Transient Cerebral Ischemia

Drugs for Transient Cerebral Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 317)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-78-2 2244
2
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
3
Amlodipine Approved Phase 4,Phase 3 88150-42-9 2162
4
Losartan Approved Phase 4 114798-26-4 3961
5
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 55142-85-3 5472
6
Dalteparin Approved Phase 4,Phase 2 9041-08-1
7
Candesartan Approved Phase 4,Phase 3 139481-59-7 2541
8
Cilostazol Approved Phase 4,Phase 3 73963-72-1 2754
9
Warfarin Approved Phase 4,Phase 2,Phase 3 81-81-2 6691 54678486
10
Rivaroxaban Approved Phase 4,Phase 2,Phase 3 366789-02-8
11 Edoxaban Approved Phase 4,Phase 2,Phase 3 480449-70-5
12
Dipyridamole Approved Phase 4,Phase 3 58-32-2 3108
13
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
14
Nicotine Approved Phase 4 54-11-5 942 89594
15
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
16
Metformin Approved Phase 4 657-24-9 14219 4091
17
Everolimus Approved Phase 4,Phase 2,Phase 3 159351-69-6 6442177
18
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 22916-47-8 4189
19
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3 53123-88-9 5284616 6436030 46835353
20
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2 9005-49-6 772 46507594
21
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
22
Tranexamic Acid Approved Phase 4 1197-18-8 5526
23
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
24
Irbesartan Approved, Investigational Phase 4,Phase 3 138402-11-6 3749
25
Simvastatin Approved Phase 4,Phase 2,Phase 3 79902-63-9 54454
26
Acenocoumarol Approved Phase 4,Phase 3 152-72-7 9052 54676537
27
Phenprocoumon Approved Phase 4,Phase 3 435-97-2 9908 54680692
28
Allopurinol Approved Phase 4 315-30-0 2094
29
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
30
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
31
Fluvastatin Approved Phase 4 93957-54-1 1548972
32
Pravastatin Approved Phase 4 81093-37-0 54687
33
Propafenone Approved Phase 4 54063-53-5 4932
34
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
35
Apixaban Approved Phase 4,Phase 3 503612-47-3 10182969
36
Tinzaparin Approved Phase 4 9005-49-6, 9041-08-1 25244225
37
Clopidogrel Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 120202-66-6, 113665-84-2 60606
38
Menadione Approved, Nutraceutical Phase 4,Phase 3 58-27-5 4055
39
Phytonadione Approved, Nutraceutical Phase 4,Phase 3 84-80-0 4812 5284607
40
Ginseng Approved, Nutraceutical Phase 4 50647-08-0
41 3-n-butylphthalide Phase 4
42 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
43 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
44 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
45 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
46 Antipyretics Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
47 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
48 Cyclooxygenase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
49 Fibrinolytic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
50 Neuroprotective Agents Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 429)
id Name Status NCT ID Phase
1 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4
2 A Morbidity-Mortality and Remodeling Study With Valsartan Unknown status NCT00133328 Phase 4
3 Japanese Primary Prevention Project With Aspirin Unknown status NCT00225849 Phase 4
4 Hypertension Control Based on Home Blood Pressure Unknown status NCT00198562 Phase 4
5 Preventing Recurrent Vascular Events in Patients With Stroke or Transient Ischemic Attack Completed NCT00931788 Phase 4
6 Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke Completed NCT00924638 Phase 4
7 Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke Completed NCT00147602 Phase 4
8 ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial Completed NCT00161070 Phase 4
9 The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study) Completed NCT00250380 Phase 4
10 Efficacy and Cost-Effectiveness of Cost-free Pharmacotherapy for Smoking Cessation for High-risk Smokers With Cerebrovascular Disease Completed NCT00962988 Phase 4
11 Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Implantation: the ARTE Trial Completed NCT01559298 Phase 4
12 EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA Completed NCT00562588 Phase 4
13 Metformin-Dipyridamole Interaction Trial Completed NCT01613755 Phase 4
14 Safety and Efficacy Study Comparing 3 New Types of Coronary Stents Completed NCT01166685 Phase 4
15 Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study) Completed NCT00149227 Phase 4
16 Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II) Completed NCT00289042 Phase 4
17 Omacor in Prevention of Cardiovascular Events in Patients Undergoing Chronic Hemodialysis Completed NCT00257283 Phase 4
18 OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Completed NCT00134160 Phase 4
19 MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure Completed NCT00262119 Phase 4
20 Diuretics In the Management of Essential Hypertension (DIME) Study Completed NCT00131846 Phase 4
21 Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial Completed NCT01035450 Phase 4
22 Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan Completed NCT01069302 Phase 4
23 Tranexamic Acid Dosing for Total Joint Arthroplasty Completed NCT02584725 Phase 4
24 Myocardial Damage In Patients With Cerebral Infarction Completed NCT00306579 Phase 4
25 Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Completed NCT00262561 Phase 4
26 Reduction of Atrial Fibrillation Study in Patients Undergoing Coronary Artery Bypass Grafting. (RASCABG 1 Study) Completed NCT00287209 Phase 4
27 Xanthine Oxidase Inhibition for Improvement of Long-term Outcomes Following Ischaemic Stroke and Transient Ischaemic Attack Recruiting NCT02122718 Phase 4
28 Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD) Recruiting NCT01377285 Phase 4
29 Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives Recruiting NCT01563731 Phase 4
30 Intensive Rosuvastatin Therapy on Cerebral Hemodynamics in Patients With Atherosclerotic Intracranial Arterial Stenosis Recruiting NCT02594800 Phase 4
31 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography (RETORIC) Recruiting NCT02826200 Phase 4
32 Preventive Effects of Ginseng Against Atherosclerosis Recruiting NCT02796664 Phase 4
33 Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol? Recruiting NCT02983214 Phase 4
34 Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation Recruiting NCT03061006 Phase 4
35 Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD Recruiting NCT02046460 Phase 4
36 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis Recruiting NCT02458755 Phase 4
37 Tranexamic Acid in Revision Total Joint Arthroplasty Recruiting NCT02877381 Phase 4
38 Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial Recruiting NCT02168829 Phase 4
39 A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent AF Recruiting NCT02389218 Phase 4
40 Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF Recruiting NCT02256683 Phase 4
41 Chronotherapy With Low-dose Aspirin for Primary Prevention Recruiting NCT00725127 Phase 4
42 Randomized Anticoagulation Trial in Opcab (RATIO) Recruiting NCT02812355 Phase 4
43 Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy Active, not recruiting NCT01097967 Phase 4
44 ASCEND: A Study of Cardiovascular Events iN Diabetes Active, not recruiting NCT00135226 Phase 4
45 Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI Active, not recruiting NCT02640794 Phase 4
46 The Impact of NBP on the Collateral Circulation in ICA/M1 Occlusion Enrolling by invitation NCT02594995 Phase 4
47 The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack Not yet recruiting NCT02144831 Phase 4
48 Optimal Antithrombotic Therapy in Ischemic Stroke Patients With Non-Valvular Atrial Fibrillation and Atherothrombosis Not yet recruiting NCT03062319 Phase 4
49 Effects of Tinzaparin on Cardio-vascular Outcomes and on Blood Lipids in Diabetic Patients on Chronic Hemodialysis Suspended NCT00407641 Phase 4
50 Rosuvastatin in African Americans With Cerebrovascular Disease Terminated NCT01975194 Phase 4

Search NIH Clinical Center for Transient Cerebral Ischemia

Cochrane evidence based reviews: ischemic attack, transient

Genetic Tests for Transient Cerebral Ischemia

Anatomical Context for Transient Cerebral Ischemia

MalaCards organs/tissues related to Transient Cerebral Ischemia:

39
Brain, Eye, Heart, Spinal Cord, Endothelial, Cortex, Olfactory Bulb

Publications for Transient Cerebral Ischemia

Articles related to Transient Cerebral Ischemia:

(show top 50) (show all 435)
id Title Authors Year
1
Fetal Alcohol Exposure Alters Blood Flow and Neurological Responses to Transient Cerebral Ischemia in Adult Mice. ( 27987329 )
2017
2
Astragaloside IV attenuates cognitive impairments induced by transient cerebral ischemia and reperfusion in mice via anti-inflammatory mechanisms. ( 28011393 )
2016
3
Protective effect of I+-terpineol against impairment of hippocampal synaptic plasticity and spatial memory following transient cerebral ischemia in rats. ( 27803783 )
2016
4
Magnetic resonance imaging detection of multiple ischemic injury produced in an adult rat model of minor stroke followed by mild transient cerebral ischemia. ( 27815649 )
2016
5
Neuroprotection by progesterone after transient cerebral ischemia in stroke-prone spontaneously hypertensive rats. ( 27283379 )
2016
6
Neuroprotective effect of ischemic preconditioning via modulating the expression of adropin and oxidative markers against transient cerebral ischemia in diabetic rats. ( 27020247 )
2016
7
Long-term observation of neuronal degeneration and microgliosis in the gerbil dentate gyrus after transient cerebral ischemia. ( 27000214 )
2016
8
Neuroprotection of ischemic preconditioning is mediated by thioredoxin 2 in the hippocampal CA1 region following a subsequent transient cerebral ischemia. ( 27117068 )
2016
9
Effect of Fluoxetine on Neurogenesis in Hippocampal Dentate Gyrus after Global Transient Cerebral Ischemia in Rats. ( 27496030 )
2016
10
Neuroprotective Effects of Poly(ADP-ribose)polymerase Inhibitor Olaparib in Transient Cerebral Ischemia. ( 26869042 )
2016
11
Dapsone improves functional deficit and diminishes brain damage evaluated by 3-Tesla magnetic resonance image after transient cerebral ischemia and reperfusion in rats. ( 27321157 )
2016
12
Roles of HIF-1I+, VEGF, and NF-I_B in Ischemic Preconditioning-Mediated Neuroprotection of Hippocampal CA1 Pyramidal Neurons Against a Subsequent Transient Cerebral Ischemia. ( 27785755 )
2016
13
Increases of Catalase and Glutathione Peroxidase Expressions by Lacosamide Pretreatment Contributes to Neuroprotection Against Experimentally Induced Transient Cerebral Ischemia. ( 27209305 )
2016
14
Neuroprotective effect of ischemic preconditioning via modulating the expression of cerebral miRNAs against transient cerebral ischemia in diabetic rats. ( 27635859 )
2016
15
Improved long-term outcome after transient cerebral ischemia in aquaporin-4 knockout mice. ( 26767580 )
2016
16
Transient cerebral ischemia in an elderly patient with patent foramen ovale and atrial septal aneurysm. ( 26379429 )
2015
17
Ischemic preconditioning protects neurons from damage and maintains the immunoreactivity of kynurenic acid in the gerbil hippocampal CA1A region following transient cerebral ischemia. ( 25872573 )
2015
18
Neuroprotection and reduced gliosis by atomoxetine pretreatment in a gerbil model of transient cerebral ischemia. ( 26671145 )
2015
19
Monocarboxylate transporter 4 plays a significant role in the neuroprotective mechanism of ischemic preconditioning in transient cerebral ischemia. ( 26692857 )
2015
20
Transient Cerebral Ischemia Promotes Brain Mitochondrial Dysfunction and Exacerbates Cognitive Impairments in Young 5xFAD Mice. ( 26632816 )
2015
21
Ischemic preconditioning maintains the immunoreactivities of glucokinase and glucokinase regulatory protein in neurons of the gerbil hippocampal CA1 region following transient cerebral ischemia. ( 26134272 )
2015
22
Permeability Parameters Measured with Dynamic Contrast-Enhanced MRI: Correlation with the Extravasation of Evans Blue in a Rat Model of Transient Cerebral Ischemia. ( 26175578 )
2015
23
Impact of hyperthermia before and during ischemia-reperfusion on neuronal damage and gliosis in the gerbil hippocampus induced by transient cerebral ischemia. ( 25434714 )
2015
24
Neuroprotection of Ischemic Preconditioning is Mediated by Anti-inflammatory, Not Pro-inflammatory, Cytokines in the Gerbil Hippocampus Induced by a Subsequent Lethal Transient Cerebral Ischemia. ( 26290267 )
2015
25
Ischemia-Induced Changes of PRAS40 and p-PRAS40 Immunoreactivities in the Gerbil Hippocampal CA1 Region After Transient Cerebral Ischemia. ( 26526334 )
2015
26
Upregulation of the GEF-H1 pathway after transient cerebral ischemia. ( 25447939 )
2015
27
Failure in neuroprotection of remote limb ischemic postconditioning in the hippocampus of a gerbil model of transient cerebral ischemia. ( 26454372 )
2015
28
DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice. ( 25986579 )
2015
29
Up-Regulation of TREK-2 Potassium Channels in Cultured Astrocytes Requires De Novo Protein Synthesis: Relevance to Localization of TREK-2 Channels in Astrocytes after Transient Cerebral Ischemia. ( 25886567 )
2015
30
Effects of Etanercept against Transient Cerebral Ischemia in Diabetic Rats. ( 26665003 )
2015
31
Valeriana officinalis Extracts Ameliorate Neuronal Damage by Suppressing Lipid Peroxidation in the Gerbil Hippocampus Following Transient Cerebral Ischemia. ( 25785762 )
2015
32
A Water-Ethanol Extract from the Willow Bracket Mushroom, Phellinus igniarius (Higher Basidiomycetes), Reduces Transient Cerebral Ischemia-Induced Neuronal Death. ( 26756300 )
2015
33
Hemodynamic variability and cerebrovascular control after transient cerebral ischemia. ( 26537345 )
2015
34
Sitagliptin attenuates transient cerebral ischemia/reperfusion injury in diabetic rats: Implication of the oxidative-inflammatory-apoptotic pathway. ( 25721294 )
2015
35
CXCR-7 receptor promotes SDF-1I+-induced migration of bone marrow mesenchymal stem cells in the transient cerebral ischemia/reperfusion rat hippocampus. ( 24924806 )
2014
36
Ionizing radiation as preconditioning against transient cerebral ischemia in rats. ( 25032511 )
2014
37
Neuroprotection by platelet-activating factor acetylhydrolase in a mouse model of transient cerebral ischemia. ( 24189491 )
2014
38
EAAC1 Gene Deletion Increases Neuronal Death and Blood Brain Barrier Disruption after Transient Cerebral Ischemia in Female Mice. ( 25350110 )
2014
39
Delayed remote ischemic postconditioning protects against transient cerebral ischemia/reperfusion as well as kainate-induced injury in rats. ( 24935779 )
2014
40
Effect of transient cerebral ischemia on the expression of receptor for advanced glycation end products (RAGE) in the gerbil hippocampus proper. ( 24880882 )
2014
41
Low doses of the selective adenosine A2A receptor agonist CGS21680 are protective in a rat model of transient cerebral ischemia. ( 24457041 )
2014
42
The effect of a microcatheter-based selective intra-arterial hypothermia on hemodynamic changes following transient cerebral ischemia. ( 25310355 )
2014
43
Expression of brain adiponectin in a murine model of transient cerebral ischemia. ( 25550990 )
2014
44
Evaluation of survival and neurological deficit in rats in the new model of global transient cerebral ischemia. ( 25430646 )
2014
45
Asiaticoside attenuates memory impairment induced by transient cerebral ischemia-reperfusion in mice through anti-inflammatory mechanism. ( 24631487 )
2014
46
Potential targets for protecting against hippocampal cell apoptosis after transient cerebral ischemia-reperfusion injury in aged rats. ( 25206771 )
2014
47
Genistein attenuates brain damage induced by transient cerebral ischemia through up-regulation of ERK activity in ovariectomized mice. ( 24719563 )
2014
48
Treatment with lutein provides neuroprotection in mice subjected to transient cerebral ischemia. ( 25080968 )
2014
49
Effects of ischemic preconditioning on VEGF and pFlk-1 immunoreactivities in the gerbil ischemic hippocampus after transient cerebral ischemia. ( 25300771 )
2014
50
Effects of Agmatine on Blood-Brain Barrier Stabilization Assessed by Permeability MRI in a Rat Model of Transient Cerebral Ischemia. ( 25273536 )
2014

Variations for Transient Cerebral Ischemia

Expression for Transient Cerebral Ischemia

Search GEO for disease gene expression data for Transient Cerebral Ischemia.

Pathways for Transient Cerebral Ischemia

Pathways related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.65 CASP3 HSPA1A HSPA4 HSPA5 IL1B
2 12.43 CASP3 HSPA1A HSPA5 IL1B MAPT
3
Show member pathways
12.11 CCL2 IL1B KMO KYNU
4
Show member pathways
12.09 CASP3 CCL2 IL1B LCN2
5 12.06 GRIN2A MAP2 MAPT NOTCH3 SLC1A1
6
Show member pathways
12.05 CASP3 CCL2 MAP2 PTK2B
7 11.85 CASP3 CCL2 IL1B
8
Show member pathways
11.82 CASP3 GRIN2A SLC1A1
9 11.81 CCL2 IL1B LCN2
10 11.78 CASP3 CCL2 IL1B
11
Show member pathways
11.72 HSPA1A HSPA4 HSPA5
12 11.71 CASP3 CCL2 IL1B
13 11.42 CASP3 MAPT PTK2B
14
Show member pathways
11.32 HSPA1A HSPA4 HSPA5
15 11.24 CASP3 HSPA1A IL1B
16 11.05 HSPA1A HSPA4 HSPA5
17 10.76 CCL2 IL1B
18 10.68 HSPA1A HSPA5 IL1B
19 10.64 MAP2 MAPT
20 10.34 HSPA1A HSPA4 HSPA5

GO Terms for Transient Cerebral Ischemia

Cellular components related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.44 CASP3 GCKR HSPA1A HSPA4 IL1B KMO
2 nuclear periphery GO:0034399 9.16 MAP2 MAPT
3 NMDA selective glutamate receptor complex GO:0017146 8.96 GRIN2A PTK2B

Biological processes related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

(show all 22)
id Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.86 CCL2 GRIN2A IL1B PTK2B
2 response to ethanol GO:0045471 9.77 CCL2 GRIN2A PTK2B
3 response to wounding GO:0009611 9.67 CASP3 CCL2 GRIN2A
4 cellular response to organic cyclic compound GO:0071407 9.65 CASP3 CCL2 IL1B
5 cellular response to drug GO:0035690 9.63 CCL2 HSPA5 IL1B
6 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.61 DRD1 PTK2B
7 memory GO:0007613 9.61 DRD1 GRIN2A MAPT
8 long term synaptic depression GO:0060292 9.59 DRD1 PTK2B
9 chaperone-mediated protein complex assembly GO:0051131 9.58 HSPA1A HSPA4
10 NAD biosynthetic process GO:0009435 9.58 KMO KYNU
11 dopamine metabolic process GO:0042417 9.57 DRD1 GRIN2A
12 tryptophan catabolic process GO:0006569 9.55 KMO KYNU
13 PERK-mediated unfolded protein response GO:0036499 9.54 CCL2 HSPA5
14 long-term synaptic potentiation GO:0060291 9.54 DRD1 GRIN2A PTK2B
15 pyridine nucleotide biosynthetic process GO:0019363 9.52 KMO KYNU
16 regulation of calcium-mediated signaling GO:0050848 9.51 MAPT PTK2B
17 response to cocaine GO:0042220 9.5 DRD1 HSPA5 PTK2B
18 cellular response to organic substance GO:0071310 9.43 CASP3 IL1B MAP2
19 tryptophan catabolic process to kynurenine GO:0019441 9.4 KMO KYNU
20 quinolinate biosynthetic process GO:0019805 9.16 KMO KYNU
21 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.13 CASP3 IL1B LCN2
22 response to drug GO:0042493 9.1 CASP3 CCL2 DRD1 GRIN2A LCN2 PTK2B

Molecular functions related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.1 GCKR HSPA1A HSPA5 MAPT NOTCH3 PTK2B
2 NMDA glutamate receptor activity GO:0004972 8.96 GRIN2A PTK2B

Sources for Transient Cerebral Ischemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....